An improved oral vaccine with molecular adjuvant β-defensin protects grouper against nervous necrosis virus infection. Issue 136 (May 2023)

• Record Type: Journal Article
• Authors: Zheng, Jiaying; Yang, Jiahui; Zhang, Zemiao; Liang, Xia; Liu, Shijia; Pan, Ying; Wei, Jingguang; Huang, Youhua; Huang, Xiaohong; Qin, Qiwei
• Is Part Of: Fish & shellfish immunology. Issue 136(2023)
• Publication Date: 2023-05
• Subjects: Grouper -- RGNNV -- β-defensin -- Molecular adjuvant -- Oral vaccines; Fishes -- Immunology -- Periodicals; Shellfish -- Immunology -- Periodicals; Poissons -- Immunologie -- Périodiques; Crustacés -- Immunologie -- Périodiques; 571.9617
• DOI: 10.1016/j.fsi.2023.108709
• Languages: English
• ISSNs: 1050-4648

Abstract

Abstract: Nervous necrosis virus (NNV) is one of the most important fish viral pathogens infecting more than 120 fish species worldwide. Due to the mass mortality rates often seen among larvae and juveniles, few effective vaccines against NNV were developed up to now. Here, the protective effect of recombinant coat protein (CP) from red-spotted grouper nervous necrosis virus (RGNNV) fused with grouper β-defensin (DEFB) as an oral vaccine was evaluated using Artemia as a biocarrier delivery system in pearl gentian grouper ( Epinephelus lanceolatus ♂ × Epinephelus fuscoguttatus ♀). Feeding with Artemia encapsulated with E. coli expressing control vector (control group), CP, or CP-DEFB showed no obvious side effects on the growth of groupers. ELISA and antibody neutralization assay showed that CP-DEFB oral vaccination group induced higher anti-RGNNV CP specific antibodies and exhibited higher neutralization potency than the CP and control group. Meanwhile, the expression levels of several immune and inflammatory factors in the spleen and kidney after feeding with CP-DEFB were also significantly increased compared with the CP group. Consistently, after challenge with RGNNV, groupers fed CP-DEFB and CP exhibited 100% and 88.23% relative percentage survival (RPS), respectively. Moreover, the lower transcription levels of viral genes and milder pathological changes in CP-DEFB group were detected compared with the CP and control group. Thus, we proposed that grouper β-defensin functioned as an efficient molecular adjuvant for an improved oral vaccine against nervous necrosis virus infection. Highlights: The fusion protein of CP-DEFB was constructed by three parts. The CP-DEFB oral vaccine induced protective immunity in pearl gentian grouper. The serum of the CP-DEFB group had the stronger antiviral ability. The CP-DEFB have stronger expression of immune-related genes after immunization.